Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATYR NASDAQ:KPRX NASDAQ:NBRV NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.48+1.5%$0.68$0.40▼$7.29$45.93M0.553.60 million shs1.22 million shsKPRXKiora Pharmaceuticals$2.60-1.1%$2.49$1.76▼$3.29$11.66M-0.438,807 shs6,816 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/ATVGNTevogen Bio$11.67+10.1%$7.77$4.14▼$71.00$44.14M0.1444,047 shs14,742 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+1.49%-7.33%-10.34%-44.07%-91.18%KPRXKiora Pharmaceuticals-1.14%-1.14%+6.56%+24.40%-17.72%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%-98.00%TVGNTevogen Bio+10.09%+18.36%+67.43%+116.91%-82.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATYRaTyr Pharma$0.48+1.5%$0.68$0.40▼$7.29$45.93M0.553.60 million shs1.22 million shsKPRXKiora Pharmaceuticals$2.60-1.1%$2.49$1.76▼$3.29$11.66M-0.438,807 shs6,816 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shsN/ATVGNTevogen Bio$11.67+10.1%$7.77$4.14▼$71.00$44.14M0.1444,047 shs14,742 shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATYRaTyr Pharma+1.49%-7.33%-10.34%-44.07%-91.18%KPRXKiora Pharmaceuticals-1.14%-1.14%+6.56%+24.40%-17.72%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%-98.00%TVGNTevogen Bio+10.09%+18.36%+67.43%+116.91%-82.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATYRaTyr Pharma 2.25Hold$21.004,317.33% UpsideKPRXKiora Pharmaceuticals 2.00Hold$10.00284.62% UpsideNBRVNabriva Therapeutics 0.00N/AN/AN/ATVGNTevogen Bio 1.50Reduce$100.00756.90% UpsideCurrent Analyst Ratings BreakdownLatest KPRX, NBRV, TVGN, and ATYR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026ATYRaTyr Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/20/2026ATYRaTyr Pharma Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy4/27/2026KPRXKiora Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026TVGNTevogen Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATYRaTyr Pharma$190K245.33N/AN/A$0.69 per share0.69KPRXKiora Pharmaceuticals$16.02M0.72N/AN/A$4.38 per share0.59NBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00TVGNTevogen BioN/AN/AN/AN/A($211.84) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATYRaTyr Pharma-$74.12M-$0.73N/AN/AN/AN/A-100.14%-73.55%8/6/2026 (Estimated)KPRXKiora Pharmaceuticals-$10.84M-$2.71N/AN/AN/AN/A-59.30%-41.23%8/7/2026 (Estimated)NBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ATVGNTevogen Bio-$26.27M-$4.61N/AN/AN/AN/AN/A-472.77%8/13/2026 (Estimated)Latest KPRX, NBRV, TVGN, and ATYR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ATYRaTyr Pharma-$0.16-$0.11+$0.05-$0.11N/AN/A5/15/2026Q1 2026TVGNTevogen Bio-$2.64-$1.61+$1.03-$1.61N/AN/A5/8/2026Q1 2026KPRXKiora Pharmaceuticals-$0.58-$0.58N/A-$0.58$1.50 millionN/A3/25/2026Q4 2025KPRXKiora Pharmaceuticals-$0.70-$1.60-$0.90-$1.60$1.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthATYRaTyr PharmaN/AN/AN/AN/AN/AKPRXKiora PharmaceuticalsN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ATVGNTevogen BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATYRaTyr PharmaN/A5.785.78KPRXKiora PharmaceuticalsN/A6.686.68NBRVNabriva Therapeutics0.120.850.52TVGNTevogen BioN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATYRaTyr Pharma61.72%KPRXKiora Pharmaceuticals76.97%NBRVNabriva Therapeutics0.27%TVGNTevogen BioN/AInsider OwnershipCompanyInsider OwnershipATYRaTyr Pharma5.75%KPRXKiora Pharmaceuticals0.05%NBRVNabriva Therapeutics1.63%TVGNTevogen Bio70.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATYRaTyr Pharma5398.05 million92.41 millionOptionableKPRXKiora Pharmaceuticals104.43 million4.43 millionNot OptionableNBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableTVGNTevogen Bio34.16 million1.23 millionN/AKPRX, NBRV, TVGN, and ATYR HeadlinesRecent News About These CompaniesTevogen Bio Inc: Tevogen Announces Formation of a Healthcare Services InitiativeJune 10 at 1:47 PM | finanznachrichten.deTevogen Bio Holdings Inc. Announces William Keane as Interim Head of New Healthcare Services Initiative, Exploring MSO and CRO AcquisitionsJune 9 at 3:51 PM | quiverquant.comQTevogen Announces Formation of a Healthcare Services InitiativeJune 9 at 3:30 PM | globenewswire.comTevogen Bio (NASDAQ:TVGN) Trading 6.2% Higher - Should You Buy?June 6, 2026 | americanbankingnews.comTevogen Bio Inc: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | finanznachrichten.deTevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 ...May 28, 2026 | enidnews.comETevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual RevenueMay 28, 2026 | globenewswire.comTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services ...May 21, 2026 | caledonianrecord.comCTevogen Bio Holdings Inc. Signs Non-Binding Letter of Intent to Explore Strategic Healthcare TransactionMay 21, 2026 | quiverquant.comQTevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services OrganizationMay 21, 2026 | globenewswire.comTevogen Bio Holdings Inc. Reports Significant Operational Improvements and Strategic Growth InitiativesMay 18, 2026 | quiverquant.comQLetter to Shareholders from CEO Dr. Ryan SaadiMay 18, 2026 | globenewswire.comTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest ...May 12, 2026 | caledonianrecord.comCTevogen Bio Holdings Inc. Secures $3 Million PIPE Financing from The Patel Family, LLPMay 12, 2026 | quiverquant.comQTevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market CloseMay 12, 2026 | globenewswire.comTevogen (TVGN) Soars 11% as Firm Gears Up for AI Training CommercializationMay 5, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | finance.yahoo.comTevogen.AI Nears Completion of PredicTcellâ„¢ Training; Initiates Commercial Readiness and Debuts Internal Application PortalApril 27, 2026 | globenewswire.comTevogen Bio krijgt melding van Nasdaq wegens niet-naleving beursregelsApril 23, 2026 | nl.investing.comTevogen Bio Faces Nasdaq Market Value Compliance ChallengesApril 22, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKPRX, NBRV, TVGN, and ATYR Company DescriptionsaTyr Pharma NASDAQ:ATYR$0.48 +0.01 (+1.49%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$0.46 -0.02 (-3.24%) As of 06/11/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.Kiora Pharmaceuticals NASDAQ:KPRX$2.60 -0.03 (-1.14%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$2.56 -0.04 (-1.54%) As of 06/11/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.Tevogen Bio NASDAQ:TVGN$11.67 +1.07 (+10.09%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$11.50 -0.17 (-1.46%) As of 06/11/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Microsoft Just Gave Investors 3 Dates They Can't Afford to Ignore SpaceX IPO Fears Are Overblown, But the AI Bet Is Real The Biggest Opportunity From SpaceX’s IPO May Surprise You NVIDIA’s Outlook Gains Momentum: Stock Price to Follow Chewy’s Growth Engine Is Stronger Than the Market Thinks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
